Subscribe
shutterstock_2131359385_sruilk
9 November 2023BiotechnologyMarisa Woutersen

Taiwan company fails to overturn PTAB decision over eye treatment patent

Federal Circuit rejects appeal in patent dispute with California’s Cloudbreak Theraputics | Court stated failure to prove concrete injury.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis sues Regeneron over eye treatment
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.
Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Novartis sues Regeneron over eye treatment
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.
Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.

More on this story

Americas
Novartis sues Regeneron over eye treatment
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.
Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers